News | November 17, 2008

Ascent Receives 510(k) Clearance for Reprocessed Biosense Webster LASSO Circular Mapping Catheters

November 18, 2008 - Ascent Healthcare Solutions, said yesterday it received the industry's first 510(k) clearance from the FDA to reprocess the LASSO 2515 Variable Circular Mapping Catheter manufactured by Biosense Webster.

With this new clearance, Ascent continues to increase its portfolio of EP catheters to offer EP cath labs the ability to most effectively manage their resources while ensuring that clinicians have access to their preferred device to most effectively diagnose arrhythmias, the company said.

The average price for these reprocessed circular mapping catheters is $700; a savings of 53-58 percent, compared with the national average cost of $1,500-$1,650 when these devices are purchased directly from the original manufacturer. Ascent's focus on providing reprocessing and remanufacturing services for a wide range of high-cost, high-volume devices enables its hospital partners to reallocate its savings to staffing, services and technology that improve patient care. Hospitals using Ascent's services also help protect the environment through reprocessing, recycling and material reclamation, the company said.

The Biosense Webster LASSO 2515 Variable Circular Mapping Catheter has been designed to facilitate electrophysiological mapping of the atria of the heart and is deployed in the right or left atrium. The catheter features a variable loop that easily adjusts to any vein sized between 25 and 15 mm. Its adjustable tip provides efficient mapping and is also deflectable for maximum movement. It is available in 10 and 20-electrode configurations. These devices will be the first line of reprocessed diagnostic EP catheters to be packaged in Ascent's thermoformed tray.

For more information: www.ascenths.com


Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2023 — Findings from two new studies highlight the success of left bundle branch area pacing (LBBAP), or his ...

Home May 22, 2023
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2023 — Results from a pivotal clinical trial found a leadless pacemaker can deliver cardiac resynchronization ...

Home May 22, 2023
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Subscribe Now